Therapeutic Strategies for Metastatic Melanoma

Metastatic melanoma is characterised by its high propensity for dissemination and historically poor survival. Over the past decade, treatment has shifted from cytotoxic chemotherapy towards precision and immune-based approaches. Targeted therapies, principally BRAF and MEK inhibitors, exploit oncogenic mutations to induce rapid tumour regression, while immune checkpoint inhibitors directed against CTLA-4 and PD-1 pathways have unlocked durable responses by reinvigorating T-cell activity. Adoptive cell transfer and oncolytic viruses further expand the immunotherapeutic arsenal, with emerging strategies seeking to modulate the tumour microenvironment and overcome primary or acquired resistance. Combination regimens that integrate targeted agents with checkpoint blockade have demonstrated synergistic efficacy but require careful management of toxicity. Novel delivery platforms, such as nanoparticle or protein-based carriers, aim to enhance drug concentration within metastatic sites and reduce off-target effects. Antiangiogenic agents and radiotherapy retain a complementary role, particularly for symptom control and eradication of sanctuary sites. Contemporary research also explores metabolic reprogramming, epigenetic modifiers and gene-editing technologies to broaden the therapeutic index. Collectively, these advances underline a global paradigm shift towards personalised, multi-modal strategies that balance rapid tumour control with sustained immune surveillance.

Research from Nature Portfolio

Recent studies have elucidated how dysregulation of RNA-binding proteins contributes to immune escape in metastatic melanoma. Detailed structural analyses reveal that the tandem KH domains of a specific E3 ubiquitin ligase bind HLA-A mRNA with high affinity, directing its degradation and impairing antigen presentation. This discovery provides a molecular blueprint for therapeutic inhibition of the RNA-protein interface, potentially restoring tumour immunogenicity and augmenting checkpoint-blockade efficacy. Insights into the dynamic interactions between these domains and their RNA substrates offer a foundation for rational design of small-molecule inhibitors or peptidomimetics aimed at reversing immune evasion.

Therapeutic Strategies for Metastatic Melanoma publication trend

The graph below shows the total number of articles in therapeutic strategies for metastatic melanoma across all publications each year (not limited to Nature Index journals).

Technical terms

Immune checkpoint inhibitor: Antibody that blocks regulatory pathways (e.g. CTLA-4, PD-1) to enhance T-cell-mediated tumour destruction.

BRAF inhibitor: Small molecule targeting mutant BRAF kinase to interrupt MAPK signalling and induce melanoma cell apoptosis.

Adoptive cell transfer: Infusion of autologous or engineered T cells with tumour-specific receptors to eradicate metastatic lesions.

Tumour microenvironment: The cellular, vascular and extracellular network surrounding tumour cells that modulates growth and therapy response.

hMEX3B: An RNA-binding E3 ubiquitin ligase that recognises HLA-A transcripts and promotes their degradation, facilitating immune escape.

References

1. Molecular mechanism of specific HLA-A mRNA recognition by the RNA-binding-protein hMEX3B to promote tumor immune escape. Communications Biology (2024).
2. The role of mitochondria in the resistance of melanoma to PD-1 inhibitors. Journal of Translational Medicine (2023).
3. Microparticles Made with Silk Proteins for Melanoma Adjuvant Therapy. Gels (2024).
4. Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies. Frontiers in Pharmacology (2023).
5. Role of radiotherapy in melanoma management. Radiology and Oncology (2010).